Mills, A., Richmond, G. J., Newman, C., Osiyemi, O., Cade, J., Brinson, C., . . . Spreen, W. (2020). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open Forum Infect Dis.
Chicago Stili AlıntıMills, Anthony, et al. "116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results From the POLAR Study." Open Forum Infect Dis 2020.
MLA AlıntıMills, Anthony, et al. "116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results From the POLAR Study." Open Forum Infect Dis 2020.